Gene · 8808
IL36R: interleukin 36 receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. IL36R: interleukin 36 receptor. Genes, record 8808. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8808
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9HB29 | Interleukin-1 receptor-like 2 | 575 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents71
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4757832 A1 | 2026-06-17 | 4 | Q9HB29 | Espacenet |
| JP 2026506716 A | 2026-02-25 | 1 | Q9HB29 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 50145 | Q9HB29 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 50148 | Q9HB29 | Espacenet |
| EP 4671282 A1 | 2025-12-31 | 1 | Q9HB29 | Espacenet |
| JP 2025172069 A | 2025-11-20 | 223 | Q9HB29 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2330 | Q9HB29 | Espacenet |
| US 12471579 B2 | 2025-11-18 | 2 | Q9HB29 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1892 | Q9HB29 | Espacenet |
| KR 1020250153801 A | 2025-10-27 | 1 | Q9HB29 | Espacenet |
1 to 10 of 71
See all 71 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials33
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06886009 | SPESOLIMAB | ClinicalTrials.gov | ||
| NCT06624670 | SPESOLIMAB | PHASE3 | ClinicalTrials.gov | |
| NCT06241573 | SPESOLIMAB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06092216 | SPESOLIMAB | PHASE2 | ClinicalTrials.gov | |
| NCT05856526 | SPESOLIMAB | PHASE2/PHASE3 | 2026-03-12 | ClinicalTrials.gov |
| NCT05819398 | SPESOLIMAB | PHASE2/PHASE3 | 2025-11-05 | ClinicalTrials.gov |
| NCT05670821 | SPESOLIMAB | ClinicalTrials.gov | ||
| NCT05366855 | IMSIDOLIMAB | PHASE3 | ClinicalTrials.gov | |
| NCT05352893 | IMSIDOLIMAB | PHASE3 | 2026-03-17 | ClinicalTrials.gov |
| NCT05239039 | SPESOLIMAB | PHASE3 | 2024-10-09 | ClinicalTrials.gov |
1 to 10 of 33
See all 33 trialsNIH grants644
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IL36R papers | Newest fiscal year |
|---|---|---|---|
| R01AI015614 | Pathogenesis of Fever in Man | 8 | 2025 |
| ZIDAR041180 | Clinical Support Services for the NIAMS Intramural Research Program | 4 | 2025 |
| ZIAAI001220 | Pathogenesis, and Outcome of Autoinflammatory Diseases, NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's-like Diseases, and other Undifferentiated Autoinflammatory Diseases | 3 | 2025 |
| ZIEAR041176 | Clinical Training in Rheumatology | 3 | 2025 |
| P30AR075043 | University of Michigan Skin Biology and Diseases Resource-based Center | 2 | 2025 |
| P30CA072720 | Cancer Center Support Grant | 2 | 2025 |
| P30DK097948 | The Cleveland Digestive Diseases Research Core Center (DDRCC) | 2 | 2025 |
| P30EY003790 | Core Grant for Vision Research | 2 | 2025 |
| P30EY004068 | Core Grant for Vision Research | 2 | 2025 |
| R01AI163029 | Inborn errors of immunity in patients with life-threatening COVID-19 | 2 | 2025 |
1 to 10 of 644Source NIH's project files
See all 644 nih grantsPapers947
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| An Evolving Landscape in GPP Management: Recibokibart and the Prospect of Broader Access to IL-36 Receptor Blockade. | Br J Dermatol | 2026 | 42710062 | PubTator, text mining | PubMed |
| Japanese intractable and rare dermatologic diseases: From the official skin-centered nanbyo core to an illustrative mechanism-based framework. | Intractable Rare Dis Res | 2026 | 42643679 | PubTator, text mining | PubMed |
| Author Correction: IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation. | Nat Immunol | 2026 | 42608477 | PubTator, text mining | PubMed |
| Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis. | Pragmat Obs Res | 2026 | 42604245 | PubTator, text mining | PubMed |
| INDIVIDUAL ARTICLE: Generalized Pustular Psoriasis: A Contemporary Review of Diagnosis, Pathophysiology, and IL-36 Pathway-Directed Management. | J Drugs Dermatol | 2026 | 42555081 | PubTator, text mining | PubMed |
| When Conventional Therapy Fails: Interleukin-36 Inhibition for Severe Hydroxychloroquine-Induced Acute Generalized Exanthematous Pustulosis in Systemic Lupus Erythematosus - A Case Report. | Case Rep Dermatol | 2026 | 42524626 | PubTator, text mining | PubMed |
| Mitochondrial and Epigenetic Drivers of Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. | Antioxidants (Basel) | 2026 | 42510568 | PubTator, text mining | PubMed |
| A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis. | Am J Clin Exp Immunol | 2026 | 42487722 | PubTator, text mining | PubMed |
| Management of Generalized Pustular Psoriasis Flare with Intravenous Spesolimab Followed by Long-Term Treatment with Subcutaneous Spesolimab: A Case Report. | Case Rep Dermatol | 2026 | 42396388 | PubTator, text mining | PubMed |
| IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy. | Int J Mol Sci | 2026 | 42196416 | PubTator, text mining | PubMed |
1 to 10 of 947
See all 947 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8808
GET https://conductscience.org/api/genes/v1/8808/patents?page=2